It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.
AbbVie receives US FDA approval for Emblaveo to treat adults with complicated intra-abdominal infections with limited or no treatment options: North Chicago, Illinois Monday, Febr ...
Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...
AbbVie (ABBV) announced that the U.S. Food and Drug Administration has approved EMBLAVEO, as the first and only fixed-dose, intravenous, ...
4d
AbbVie (ABBV) announced the U.S. Food and Drug Administration approval of Emblaveo (aztreonam and avibactam). This marks the first ...
AbbVie has announced that the U.S. Food and Drug Administration (FDA) has approved EMBLAVEO (aztreonam and avibactam), as a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback